XXXIII Congreso Nacional de la Sociedad Española de Trombosis y Hemostasia

Ponencias 65 5. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012;107:985-97. 6. Amiral J, Dunois C, Amiral C, Seghatchian J. An update on labo- ratory measurements of Dabigatran: Smart specific and calibrated dedicated assays for measuring anti-IIa activity in plasma. Transfus Apher Sci 2016;54:428-37. 7. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory mea- surement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010;104:1263-71. 8. Samama MM, Contant G, Spiro TE, Perzborn E, Le Flem L, Guinet C, et al. Laboratory assessment of rivaroxaban: a review. Thromb J 2013;11:11. DOI: 10.1186/1477-9560-11-11. 9. Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M. Pro- thrombinase-induced clotting time assay for determination of the anticoa- gulant effects of unfractionated and low-molecular-weight heparins, fon- daparinux, and thrombin inhibitors.Am J Clin Pathol 2008;130:446-54. 10. Sennesael AL, Exner T, Chatelain B, Lessire S, Larock AS, Van- craeynest C, et al. An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants. Thromb Res 2017;157:29-37. 11. Douxfils J, Chatelain B, Chatelain C, Dogne JM, Mullier F. Edox- aban: Impact on routine and specific coagulation assays. A practi- cal laboratory guide. Thromb Haemost 2016;115:368-81. 12. Casutt M, Konrad C, Schuepfer G. Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM™. Anaesthesist 2012;61:948-53. 13. Harenberg J, Du S, Krämer S, Weiss C, Krämer R, Wehling M. Patients’ serum and urine as easily accessible samples for the mea- surement of non-vitamin K antagonist oral anticoagulants. Semin Thromb Hemost 2015;41:228-36. 14. Harenberg J, Du S, Wehling M, Zolfaghari S, Weiss C, Krämer R, Walenga J. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study. Clin Chem Lab Med 2016;54:275-83.